Modified transferrin-antibody fusion proteins
AssigneeBiorexis Pharmaceutical Corporation
InventorsHomayoun Sadeghi, Christopher P. Prior, Andrew Turner
Life of this patent
Estimating the term…
Abstract
Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
Claims101
A fusion protein comprising a transferrin (Tf) protein exhibiting reduced glycosylation fused to at least one antibody variable region.
A fusion protein comprising a transferrin (Tf) protein exhibiting reduced affinity for a transferrin receptor (TfR) fused to at least one antibody variable region.
A transgenic animal comprising a nucleic acid molecule of 81.
Dependencies are inferred from the claim text.